US Patent 9,206,135: Eslicarbazepine Acetate Patent Scope, Claims, Expiration and Generic Risk
US Patent 9,206,135 protects a high-purity, low-ruthenium form of eslicarbazepine acetate, the active ingredient in Aptiom. Its principal commercial value is manufacturing control: the patent claims the finished stereochemically pure compound containing about 2 ppm or less ruthenium, together with specified catalytic reduction and acylation processes. It does not broadly cover every eslicarbazepine acetate product, every dosage form, or every epilepsy treatment regimen.
The patent was granted on December 8, 2015. Its claims are directed to composition quality attributes, a defined manufacturing route, and epilepsy treatment. The nominal US patent-term endpoint appears to fall in 2031, subject to any applicable patent-term adjustment and regulatory patent-term extension. The patent’s commercial relevance depends on whether an ANDA applicant can manufacture eslicarbazepine acetate outside the claimed impurity, purity, stereochemical, and process limitations.
What drug does US Patent 9,206,135 protect?
US 9,206,135 covers eslicarbazepine acetate, also called (S)-(-)-10-acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide. The compound is the acetate prodrug of eslicarbazepine and is marketed in the United States as Aptiom for partial-onset seizures in patients four years of age and older.[1]
| Attribute |
Patent-relevant detail |
| Active ingredient |
Eslicarbazepine acetate |
| Drug product |
Aptiom tablets |
| US sponsor |
Sunovion Pharmaceuticals, now part of Sumitomo Pharma |
| Original innovator |
BIAL-Portela & C.A., S.A. |
| FDA application |
NDA 022416 |
| Therapeutic category |
Antiseizure medication |
| Patent number |
US 9,206,135 B2 |
| Grant date |
December 8, 2015 |
| Core protection |
Low-ruthenium, high-purity S-isomer |
| Regulatory pathway for competitors |
ANDA, not biosimilar pathway |
The patent concerns a small-molecule drug. Biosimilar law is therefore not relevant. A competitor would generally pursue an abbreviated new drug application demonstrating pharmaceutical equivalence and bioequivalence to Aptiom, rather than a 351(k) biologics application.
What are the independent claims in US 9,206,135?
The patent has one principal composition claim, one process-linked composition claim, and method-of-treatment claims.
Claim 1: low-ruthenium eslicarbazepine acetate
Claim 1 covers the S-isomer of eslicarbazepine acetate containing about 2 ppm or less ruthenium. The claim is not limited to a particular tablet, dose, excipient, polymorph, particle size, or dissolution profile.
Its key limitations are:
- The compound must be the S-isomer.
- The compound must be eslicarbazepine acetate.
- Ruthenium must be present at about 2 ppm or less.
Claim 3 narrows claim 1 by requiring less than 2 ppm ruthenium. The difference between "about 2 ppm or less" and "less than 2 ppm" may matter in infringement testing, especially for batches near the numerical boundary.
Claim 2: approximately 99.96% chemical purity
Claim 2 depends on claim 1 and requires approximately 99.96% chemical purity of eslicarbazepine acetate. Claims 9 and 13 repeat this purity limitation through different dependency paths.
The claim does not, based on the provided text, define:
- The analytical method used to measure purity.
- Whether purity is area percentage, weight percentage, assay, or another metric.
- The identity or permitted level of every individual impurity.
- A specific crystalline form.
- A specific enantiomeric excess value.
Those issues can become central in claim construction and infringement disputes. A generic manufacturer could challenge whether its analytical result falls within the claim or whether "about 99.96%" provides an objectively enforceable range.
Claims 4, 7 and 10: product obtained by a defined process
Claims 4, 7 and 10 require the claimed compound to be obtained by a process that includes:
- Asymmetric reduction of oxcarbazepine.
- A ruthenium catalyst prepared from a specified ruthenium complex and a ligand.
- A hydride source selected from defined amine/formate, ammonium formate, alkali-metal formate, alkaline-earth-metal formate, and formic-acid combinations.
- Maintenance of pH from 6.5 to 8.
- Acylation of the resulting S-hydroxy intermediate.
These are product-by-process limitations because the claim is formally directed to a compound "obtained by" the specified process. Under US patent law, product-by-process claims generally require the accused product to have the claimed product characteristics, while the process language can affect claim scope and infringement analysis. The practical risk is higher where the accused manufacturer uses the same ruthenium-mediated asymmetric reduction and formate-based hydride chemistry.
Claims 5, 8 and 11: absence of detectable R-isomer
These claims require the R-isomer to be below the limit of detection. They strengthen the stereochemical purity requirement but introduce an analytical-method issue. "Below the limit of detection" is not an absolute absence requirement. The relevant limit depends on the validated method, sample preparation, instrument sensitivity, and detection threshold.
Claims 15-18: epilepsy treatment
Claims 15 through 18 cover administering the claimed compound to treat epilepsy. Claim 17 duplicates claim 16 in the text supplied. That duplication does not expand the substantive scope.
These claims are narrower than a general claim to treating epilepsy because they require administration of a compound meeting the composition or process limitations incorporated through the dependency chain. Their commercial significance is limited if the drug’s approved epilepsy use was already known or if an ANDA applicant relies on a non-infringing label strategy.
How broad is the composition coverage?
The strongest claim is claim 1 because it directly covers the compound defined by stereochemistry and ruthenium content. It does not require the patented manufacturing process.
A manufacturer could potentially infringe claim 1 even if it uses a different synthetic route, provided its finished eslicarbazepine acetate contains ruthenium at or below the claimed threshold. That creates an unusual tension: the impurity limitation is both a quality specification and a potential infringement hook.
The principal scope boundaries are:
| Limitation |
Scope effect |
| S-isomer |
Excludes the R-isomer and racemic material from literal scope |
| Eslicarbazepine acetate |
Excludes eslicarbazepine, oxcarbazepine and unrelated analogs |
| About 2 ppm or less ruthenium |
Captures very low residual-ruthenium material |
| About 99.96% purity |
Adds a quantitative purity limitation |
| R-isomer below detection |
Adds an analytical stereochemical limitation |
| Specified process |
Applies only to process-linked claims |
| Epilepsy treatment |
Limits the method claims to a therapeutic use |
The patent does not appear to claim all formulations of eslicarbazepine acetate. It does not expressly claim tablets, immediate-release dosage forms, extended-release products, liquid formulations, film coatings, excipient systems, packaging, or tablet manufacturing.
What manufacturing process is protected?
The process begins with oxcarbazepine and uses asymmetric transfer hydrogenation to produce the S-hydroxy intermediate. The catalyst is based on a ruthenium complex, identified generally as [RuX2(L)]2, combined with a specified ligand class. The process uses formate chemistry and controls pH between 6.5 and 8.
The process produces:
- (S)-(+)-10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide.
- Acylation of that intermediate.
- Eslicarbazepine acetate with low residual ruthenium and high stereochemical purity.
The manufacturing limitations create several potential design-around routes:
- Use a non-ruthenium asymmetric reduction catalyst.
- Use a different ruthenium complex or ligand outside the claimed structural classes.
- Use a different reducing agent.
- Conduct the reduction outside the claimed pH range.
- Resolve or enrich the S-isomer by a different method.
- Acylate a separately prepared eslicarbazepine intermediate.
- Purify the product through a process that avoids the claimed catalyst system.
A design-around process may still face claim 1 if the final active ingredient independently satisfies the low-ruthenium limitation. Avoiding claims 4, 7 and 10 therefore does not necessarily avoid the composition claims.
What purity and impurity attributes create infringement risk?
The patent’s commercial center is residual ruthenium. Ruthenium is used in the catalytic reduction, and the claims seek to distinguish product with low catalyst residue from material containing higher levels.
A competitor’s batch should be analyzed for:
- Total ruthenium concentration.
- Enantiomeric purity.
- R-isomer detection limit.
- Overall chemical purity.
- Identity and amount of process-related impurities.
- Whether the product was made using the claimed catalyst and formate system.
- Whether the process maintained pH between 6.5 and 8.
- Whether the product can be traced to the claimed oxcarbazepine reduction sequence.
The phrase "about 2 ppm" raises a claim-construction question. A batch containing 1.9 ppm would fall within both the broad and narrower formulations. A batch containing exactly 2.0 ppm may fall within claim 1 depending on the meaning of "about," but would not satisfy a literal "less than 2 ppm" limitation in claim 3. Analytical error and method validation are likely to be important in any enforcement proceeding.
When does US Patent 9,206,135 lose exclusivity?
The patent was granted on December 8, 2015. Based on the patent’s filing and priority framework, the nominal expiration is expected in 2031, subject to patent-term adjustment.[2]
| Exclusivity component |
Expected timing |
| FDA approval of Aptiom |
November 2013 |
| New chemical entity exclusivity |
Expired in November 2018 |
| Patent grant |
December 8, 2015 |
| Nominal US patent expiration |
Approximately 2031 |
| Regulatory extension |
Requires confirmation from the patent record and Orange Book |
| Generic launch |
Controlled by remaining listed patents, litigation, settlements and court outcomes |
FDA marketing exclusivity and patent exclusivity are separate. Aptiom’s five-year new chemical entity exclusivity expired before the patent’s expected expiration. A generic could therefore submit an ANDA after NCE exclusivity ended, but patent certifications and patent litigation could delay approval or launch.[1]
The actual generic-entry date may be earlier than 2031 if a court invalidates the patent, finds it not infringed, or enforces a settlement permitting an earlier launch.
What is the Orange Book status of US 9,206,135?
The Orange Book determines whether the patent is listed against the approved NDA and whether an ANDA applicant must address it. A patent can be technically relevant to a drug yet have limited regulatory leverage if it is not listed for the approved product or if its listed claims do not cover the proposed generic product.
For an ANDA applicant, the relevant certification options generally include:
- Paragraph I: no patent information has been submitted.
- Paragraph II: the patent has expired.
- Paragraph III: the applicant will wait until expiration.
- Paragraph IV: the patent is invalid, unenforceable, or will not be infringed.
A Paragraph IV certification can trigger patent litigation if the NDA holder or patent owner files suit within the statutory period. The litigation stay can delay FDA approval for up to 30 months, subject to statutory exceptions and court action.[3]
The current Orange Book listing and any delisting, expiration-date correction, pediatric exclusivity, or regulatory exclusivity entry should be verified against the FDA’s live listing. The patent itself does not establish the current Orange Book status.
Which companies hold or commercialize the relevant rights?
BIAL developed eslicarbazepine acetate and entered into commercialization arrangements for the US market with Sunovion Pharmaceuticals. Sunovion commercialized Aptiom in the United States and is now part of Sumitomo Pharma.[4]
| Company |
Role |
| BIAL-Portela & C.A. |
Originator and patent developer |
| Sunovion Pharmaceuticals |
US commercialization and NDA sponsor for Aptiom |
| Sumitomo Pharma |
Parent organization of Sunovion |
| Generic manufacturers |
Potential ANDA filers and Paragraph IV challengers |
The patent owner, NDA holder, and commercial distributor may not be the same legal entity. That distinction matters for standing, notice, Orange Book declarations, licensing rights, and enforcement.
How does this patent compare with other eslicarbazepine acetate patents?
US 9,206,135 is primarily a quality and manufacturing patent. It differs from earlier patents that may cover the active compound, therapeutic uses, compositions, salts, or broader synthetic methods.
| Patent category |
Typical subject matter |
Relevance to US 9,206,135 |
| Active-compound patents |
Eslicarbazepine acetate and related compounds |
May have earlier expiration |
| Stereochemistry patents |
S-isomer or enantiomerically enriched material |
Overlaps with claims 1 and 5 |
| Process patents |
Reduction, resolution and acylation routes |
Overlaps with claims 4, 7 and 10 |
| Formulation patents |
Tablets, excipients, dissolution and dosage forms |
Not apparent from the supplied claims |
| Method-of-use patents |
Seizure or epilepsy treatment |
Claims 15-18 are narrower treatment claims |
| Regulatory patents |
Patents listed against NDA products |
Determines ANDA certification exposure |
The patent’s value increases if earlier active-ingredient patents have expired and this patent remains the principal barrier to low-ruthenium eslicarbazepine acetate. Its value decreases if a generic can use a non-ruthenium process and produce material outside the purity and residual-metal limitations.
What generic launch risks exist?
A generic launch faces four principal risks.
Paragraph IV litigation
A generic applicant that files a Paragraph IV certification may invite litigation over claim 1, the purity claims, the process claims, or the treatment claims. The strongest infringement theory would likely focus on the finished API’s ruthenium content rather than the manufacturing process, because claim 1 does not require the patented process.
ANDA product testing
The applicant’s own batch data may become central. The NDA holder could seek discovery concerning:
- API certificates of analysis.
- Ruthenium testing.
- Chiral impurity testing.
- Validation reports.
- Catalyst identity.
- Batch records.
- Supplier manufacturing processes.
- Purification and crystallization steps.
Process confidentiality
The product-by-process claims may require evidence of how the API was made. A generic manufacturer using a contract API supplier may face discovery and supply-chain disclosure issues.
Label and method-of-use exposure
The epilepsy method claims could present a separate theory, but their practical value depends on claim construction, approved-label content, induced-infringement evidence, and whether the generic label can omit protected uses. Because Aptiom’s principal approved indication is epilepsy, a full-label generic may have greater exposure than a carefully carved-out label.
How strong is the patent estate?
US 9,206,135 has moderate-to-strong composition claim value and narrower process claim value.
| Risk factor |
Assessment |
| Direct API claim |
Stronger because claim 1 does not require the patented process |
| Numerical impurity limit |
Enforceable in principle but vulnerable to measurement and construction disputes |
| Purity limitation |
Potentially narrow and analytically contestable |
| Stereochemical limitation |
Technically measurable and commercially relevant |
| Process claims |
Strong if the accused process uses the defined ruthenium/formate route |
| Method claims |
Narrower and more exposed to prior-art and label issues |
| Formulation coverage |
Not shown in the supplied claims |
| Biosimilar protection |
Not applicable |
| Generic design-around potential |
Meaningful, especially through non-ruthenium chemistry |
The principal weakness is claim complexity. The patent does not claim a broad class of eslicarbazepine acetate products without qualification. It claims a compound with specific quality attributes and, in several claims, a particular manufacturing history. That creates factual disputes over analytical methods, process provenance and claim construction.
What patent litigation affects Aptiom generic entry?
The supplied information does not identify a filed Paragraph IV complaint, settlement, consent judgment, or final court decision concerning US 9,206,135. A complete litigation conclusion cannot be drawn from the claim text alone.
The relevant litigation questions are:
- Is US 9,206,135 listed in the current Orange Book for Aptiom?
- Has an ANDA applicant submitted a Paragraph IV certification?
- Did the patent owner file suit within the statutory period?
- Was a 30-month stay triggered?
- Has a settlement authorized an earlier launch?
- Has a court ruled on validity, enforceability or infringement?
- Does the generic’s API contain ruthenium within the claimed range?
Without an identified case docket or current Orange Book record, the patent’s litigation status cannot be stated as active, settled, dismissed, or adjudicated.
Key Takeaways
- US 9,206,135 covers low-ruthenium eslicarbazepine acetate, not every eslicarbazepine acetate product.
- Claim 1 is the central composition claim and requires about 2 ppm or less ruthenium.
- Claims 2 and 9 add approximately 99.96% chemical purity.
- Claims 5, 8 and 11 require the R-isomer to be below the detection limit.
- Claims 4, 7 and 10 target a ruthenium-catalyzed, formate-based reduction of oxcarbazepine followed by acylation.
- Claims 15-18 cover epilepsy treatment using the claimed compound.
- The patent is a small-molecule patent, so biosimilar competition is not relevant.
- Aptiom’s NCE exclusivity expired in 2018; the remaining patent barrier is expected to extend into approximately 2031, subject to patent-term adjustment.
- A non-ruthenium manufacturing route may avoid the process claims but could still face claim 1 if the final API meets the residual-ruthenium limitation.
- Current Orange Book listing and Paragraph IV litigation status require live FDA and court-record verification.
FAQs About US Patent 9,206,135
Does US 9,206,135 cover oxcarbazepine?
No. The claims use oxcarbazepine as a starting material in specified manufacturing processes. Oxcarbazepine itself is not the claimed product.
Does the patent cover eslicarbazepine?
The claims provided are directed to eslicarbazepine acetate, not unacetylated eslicarbazepine. The process claims include an S-hydroxy intermediate before acylation, but the final claimed compound is eslicarbazepine acetate.
Can a generic avoid the patent by using a different catalyst?
Potentially, but only with respect to the process claims. A different catalyst does not automatically avoid claim 1 if the finished API contains about 2 ppm or less ruthenium and otherwise satisfies the composition limitations.
Is a tablet formulation protected by this patent?
The supplied claims do not expressly require a tablet, excipient, coating, dosage strength, dissolution profile or other formulation attribute. The patent therefore appears directed principally to the API and its manufacture.
Is a generic manufacturer required to use a Paragraph IV certification?
That depends on the patent’s current Orange Book listing, its expiration status, the ANDA applicant’s proposed product and the certification strategy selected. A patent-specific conclusion requires the current FDA listing and the applicant’s certification.
